Advertisement

Amino Acids

, Volume 42, Issue 4, pp 1133–1142 | Cite as

Methylglyoxal, glyoxalase 1 and the dicarbonyl proteome

  • Naila Rabbani
  • Paul J. ThornalleyEmail author
Review Article

Abstract

Methylglyoxal (MG) is a potent protein glycating agent. Glycation is directed to guanidino groups of arginine residues forming mainly hydroimidazolone N δ-(5-hydro-5-methyl-4-imidazolon-2-yl)-ornithine (MG-H1) residues. MG-H1 formation is damaging to the proteome as modification is often directed to functionally important arginine residues. MG-H1 content of proteins is quantified by stable isotopic dilution analysis tandem mass spectrometry and also by immunoblotting with specific monoclonal antibodies. MG-glycated proteins undergo cellular proteolysis and release MG-H1 free adduct for excretion. MG-H1 residues have been found in proteins of animals, plants, bacteria, fungi and protoctista. MG-H1 is often the major advanced glycation endproduct in proteins of tissues and body fluids, increasing in diabetes and associated vascular complications, renal failure, cirrhosis, Alzheimer’s disease, arthritis, Parkinson’s disease and ageing. Glyoxalase 1 and aldo–keto reductase 1B1 metabolise >99% MG to innocuous products and thereby protect the proteome, providing an enzymatic defence against MG-mediated glycation. Proteins susceptible to MG modification with related functional impairment are called the “dicarbonyl proteome” (DCP). DCP includes albumin, haemoglobin, transcription factors, mitochondrial proteins, extracellular matrix proteins, lens crystallins and other proteins. DCP component proteins are linked to mitochondrial dysfunction in diabetes and ageing, oxidative stress, dyslipidemia, cell detachment and anoikis and apoptosis. Biochemical and physiological susceptibility of a protein to modification by MG and sensitivity of biochemical pathways and physiological systems to related functional impairment under challenge of physiologically relevant increases in MG exposure are key concepts. Improved understanding of the DCP will likely have profound importance for human health, longevity and treatment of disease.

Keywords

Methylglyoxal Glycation Glyoxalase Proteomics Oxidative stress Ageing Diabetes Renal failure 

Notes

Acknowledgments

We thank the Wellcome Trust and British Heart Foundation for support for our glycation research.

References

  1. Abordo EA, Minhas HS, Thornalley PJ (1999) Accumulation of α-oxoaldehydes during oxidative stress. A role in cytotoxicity. Biochem Pharmacol 58:641–648PubMedCrossRefGoogle Scholar
  2. Agalou S, Ahmed N, Babaei-Jadidi R, Dawnay A, Thornalley PJ (2005) Profound mishandling of protein glycation degradation products in uremia and dialysis. J Am Soc Nephrol 16:1471–1485PubMedCrossRefGoogle Scholar
  3. Ahmed N, Argirov OK, Minhas HS, Cordeiro CA, Thornalley PJ (2002) Assay of advanced glycation endproducts (AGEs): surveying AGEs by chromatographic assay with derivatisation by aminoquinolyl-N-hydroxysuccimidyl-carbamate and application to Nε-carboxymethyl-lysine- and Nε-(1-carboxyethyl)lysine-modified albumin. Biochem J 364:1–14PubMedGoogle Scholar
  4. Ahmed N, Thornalley PJ, Dawczynski J, Franke S, Strobel J, Stein G, Haik JRGM (2003) Methylglyoxal-derived hydroimidazolone advanced glycation endproducts of human lens proteins. Invest Ophthalmol Vis Sci 44:5287–5292PubMedCrossRefGoogle Scholar
  5. Ahmed N, Ahmed U, Thornalley PJ, Hager K, Fleischer GA, Munch G (2004a) Protein glycation, oxidation and nitration marker residues and free adducts of cerebrospinal fluid in Alzheimer’s disease and link to cognitive impairment. J Neurochem 92:255–263CrossRefGoogle Scholar
  6. Ahmed N, Thornalley PJ, Luthen R, Haussinger D, Sebekova K, Schinzel R, Voelker W, Heidland A (2004b) Processing of protein glycation, oxidation and nitrosation adducts in the liver and the effect of cirrhosis. J Hepatol 41:913–919PubMedCrossRefGoogle Scholar
  7. Ahmed N, Babaei-Jadidi R, Howell SK, Beisswenger PJ, Thornalley PJ (2005a) Degradation products of proteins damaged by glycation, oxidation and nitration in clinical type 1 diabetes. Diabetologia 48:1590–1603PubMedCrossRefGoogle Scholar
  8. Ahmed N, Dobler D, Dean M, Thornalley PJ (2005b) Peptide mapping identifies hotspot site of modification in human serum albumin by methylglyoxal involved in ligand binding and esterase activity. J Biol Chem 280:5724–5732PubMedCrossRefGoogle Scholar
  9. Ahmed N, Mirshekar-Syahkal B, Kennish L, Karachalias N, Babaei-Jadidi R, Thornalley PJ (2005c) Assay of advanced glycation endproducts in selected beverages and food by liquid chromatography with tandem mass spectrometric detection. Mol Nutr Food Res 49:691–699PubMedCrossRefGoogle Scholar
  10. Ahmed N, Ahmed U, Thornalley PJ, Watts R, Tarr J, Haigh R, Winyard P (2006) Profound increase in proteolytic products of glycated and oxidised proteins in synovial fluid and plasma in osteoarthritis and rheumatoid arthritis, corrected by TNF-α antibody therapy in rheumatoid arthritis. Rheumatology 45(Suppl 1):i53Google Scholar
  11. Ahmed U, Dobler D, Larkin SJ, Rabbani N, Thornalley PJ (2008) Reversal of hyperglycemia-induced angiogenesis deficit of human endothelial cells by overexpression of glyoxalase 1 in vitro. Maillard reaction. Ann N Y Acad Sci 1126:262–264PubMedCrossRefGoogle Scholar
  12. Baba SP, Barski OA, Ahmed Y, O’Toole TE, Conklin DJ, Bhatnagar A, Srivastava S (2009) Reductive metabolism of AGE precursors: a metabolic route for preventing AGE accumulation in cardiovascular tissue. Diabetes 58:2486–2497PubMedCrossRefGoogle Scholar
  13. Bechtold U, Rabbani N, Mullineaux PM, Thornalley PJ (2009) Quantitative measurement of specific biomarkers for protein oxidation, nitration and glycation in Arabidopsis leaves. Plant J 59:661–671PubMedCrossRefGoogle Scholar
  14. Beisswenger PJ, Howell S, Touchette A, Lal S, Szwergold BS (1999) Metformin reduces systemic methylglyoxal levels in type 2 diabetes. Diabetes 48:198–202PubMedCrossRefGoogle Scholar
  15. Biemel KM, Friedl DA, Lederer MO (2002) Identification and quantification of major Maillard cross-links in human serum albumin and lens protein—evidence for glucosepane as the dominant compound. J Biol Chem 277:24907–24915PubMedCrossRefGoogle Scholar
  16. Blom N, Sicheritz-Ponten T, Gupta R, Gammeltoft S, Brunak S (2004) Prediction of post-translational glycosylation and phosphorylation of proteins from the amino acid sequence. Proteomics 4:1633–1649PubMedCrossRefGoogle Scholar
  17. Bookchin RM, Gallop PM (1968) Structure of hemoglobin A1c: nature of the N-terminal β-chain blocking group. Biochem Biophys Res Commun 32:86–93PubMedCrossRefGoogle Scholar
  18. Brouwers O, Niessen P, Haenen G, Miyata T, Brownlee M, Stehouwer C, De Mey J, Schalkwijk C (2010) Hyperglycaemia-induced impairment of endothelium-dependent vasorelaxation in rat mesenteric arteries is mediated by intracellular methylglyoxal levels in a pathway dependent on oxidative stress. Diabetologia 53:989–1000PubMedCrossRefGoogle Scholar
  19. Ceradini DJ, Yao D, Grogan RH, Callaghan MJ, Edelstein D, Brownlee M, Gurtner GC (2008) Decreasing intracellular superoxide corrects defective ischemia-induced new vessel formation in diabetic mice. J Biol Chem 283:10930–10938PubMedCrossRefGoogle Scholar
  20. Chan WH, Wu HJ, Shiao NH (2007) Apoptotic signaling in methylglyoxal-treated human osteoblasts involves oxidative stress, c-jun N-terminal kinase, caspase-3, and p21-activated kinase 2. J Cell Biochem 100:1056–1069PubMedCrossRefGoogle Scholar
  21. Chen Y, Ahmed N, Thornalley PJ (2005) Peptide mapping of human hemoglobin modified minimally by methylglyoxal in vitro. Ann N Y Acad Sci 1043:905CrossRefGoogle Scholar
  22. Delpierre G, Rider MH, Collard F, Stroobant V, Vanstapel F, Santos H, Van Schaftingen E (2000) Identification, cloning, and heterologous expression of a mammalian fructosamine-3-kinase. Diabetes 49:1627–1634PubMedCrossRefGoogle Scholar
  23. Dobler D, Ahmed N, Song LJ, Eboigbodin KE, Thornalley PJ (2006) Increased dicarbonyl metabolism in endothelial cells in hyperglycemia induces anoikis and impairs angiogenesis by RGD and GFOGER motif modification. Diabetes 55:1961–1969PubMedCrossRefGoogle Scholar
  24. Dolhofer R, Wieland OH (1979) Glycosylation of serum-albumin—elevated glycosyl-albumin in diabetic-patients. FEBS Lett 103:282–286PubMedCrossRefGoogle Scholar
  25. Dudek EJ, Shang F, Liu Q, Valverde P, Hobbs M, Taylor A (2005) Selectivity of the ubiquitin pathway for oxidatively modified proteins: relevance to protein precipitation diseases. FASEB J 19:1707–1709PubMedGoogle Scholar
  26. Duran-Jimenez B, Dobler D, Moffat S, Rabbani N, Streuli CH, Thornalley PJ, Tomlinson D, Gardiner NJ (2009) Advanced glycation endproducts in extracellular matrix proteins contribute to the failure of sensory nerve regeneration in diabetes. Diabetes 58:2893–2903PubMedCrossRefGoogle Scholar
  27. Ellis KJ (2000) Human body composition: in vivo methods. Physiol Rev 80:649–680PubMedGoogle Scholar
  28. Emsley J, Knight CG, Farndale RW, Barnes MJ, Liddington RC (2000) Structural basis of collagen recognition by integrin alpha 2 beta 1. Cell 101:47–56PubMedCrossRefGoogle Scholar
  29. Franch HA, Sooparb S, Du J (2001) A mechanism regulating proteolysis of specific proteins during renal tubular cell growth. J Biol Chem 276:19126–19131PubMedCrossRefGoogle Scholar
  30. Gallet X, Charloteaux B, Thomas A, Braseur R (2000) A fast method to predict protein interaction sites from sequences. J Mol Biol 302:917–926PubMedCrossRefGoogle Scholar
  31. Gangadhariah MH, Wang BL, Linetsky M, Henning C, Spanneberg R, Glomb MA, Nagaraj RH (2010) Hydroimidazolone modification of human alpha A-crystallin: effect on the chaperone function and protein refolding ability. Biochim Biophy Acta Mol Basis Dis 1802:432–441Google Scholar
  32. Gao Y, Wang YS (2006) Site-selective modifications of arginine residues in human hemoglobin induced by methylglyoxal. Biochemistry 45:15654–15660PubMedCrossRefGoogle Scholar
  33. Goldberg AL, Akopian TN, Kisselev AF, Lee DH (1997) Protein degradation by the proteasome and dissection of its in vivo importance with synthetic inhibitors. Mol Biol Rep 24:69–75PubMedCrossRefGoogle Scholar
  34. Gomes RA, Oliveira LMA, Silva M, Ascenso C, Quintas A, Costa G, Coelho AV, Silva MS, Ferreira AEN, Freire AP, Cordeiro C (2008) Protein glycation in vivo: functional and structural effects on yeast enolase. Biochem J 416:317–326PubMedCrossRefGoogle Scholar
  35. Gottschalk KE, Kessler H (2002) The structures of integrins and integrin–ligand complexes: implications for drug design and signal transduction. Angew Chem Int Ed 41:3767–3774CrossRefGoogle Scholar
  36. Grune T, Reinheckel T, Davies KJA (1996) Degradation of oxidized proteins in K562 human hematopoietic cells by proteasome. J Biol Chem 271:15504–15509PubMedCrossRefGoogle Scholar
  37. Henle T, Walter A, Haeßner R, Klostermeryer H (1994) Detection and identification of a protein-bound imidazolone resulting from the reaction of arginine residues and methylglyoxal. Z Lebensm Unters Forsch 199:55–58CrossRefGoogle Scholar
  38. Hernebring M, Brolen G, Aguilaniu H, Semb H, Nystrom T (2006) Elimination of damaged proteins during differentiation of embryonic stem cells. PNAS 103:7700–7705PubMedCrossRefGoogle Scholar
  39. Jerzykowski T, Matuszewski W, Tarnawski R, Winter R, Herman ZS, Sokola A (1975) Changes of certain pharmacological and biochemical indices in acute methylglyoxal poisoning. Arch Immunol Ther Exp 23:549–560Google Scholar
  40. Kang Y, Edwards LG, Thornalley PJ (1996) Effect of methylglyoxal on human leukaemia 60 cell growth: modification of DNA, G1 growth arrest and induction of apoptosis. Leuk Res 20:397–405PubMedCrossRefGoogle Scholar
  41. Karachalias N, Babaei-Jadidi R, Rabbani N, Thornalley P (2010) Increased protein damage in renal glomeruli, retina, nerve, plasma and urine and its prevention by thiamine and benfotiamine therapy in a rat model of diabetes. Diabetologia 53:1506–1516PubMedCrossRefGoogle Scholar
  42. Kim Y, Nakase H, Nagata K, Sakaki T, Maeda M, Yamamoto K (2004) Observation of arterial and venous thrombus formation by scanning and transmission electron microscopy. Acta Neurochir 146:45–51CrossRefGoogle Scholar
  43. Knight CG, Morton LF, Peachey AR, Tuckwell DS, Farndale RW, Barnes MJ (2000) The collagen-binding A-domains of integrins alpha(1)beta(1) and alpha(2)beta(1) recognize the same specific amino acid sequence, GFOGER, in native (triple-helical) collagens. J Biol Chem 275:35–40PubMedCrossRefGoogle Scholar
  44. Koenig RJ, Blobstein SH, Cerami A (1977) Structure of carbohydrate of hemoglobin A1c. J Biol Chem 252:2992–2997PubMedGoogle Scholar
  45. Kumagai T, Nangaku M, Kojima I, Nagai R, Ingelfinger JR, Miyata T, Fujita T, Inagi R (2009) Glyoxalase I overexpression ameliorates renal ischemia-reperfusion injury in rats. Am J Physiol Renal Physiol 296:F912–F921PubMedCrossRefGoogle Scholar
  46. Kurz A, Rabbani N, Walter M, Bonin M, Thornalley PJ, Auburger G, Gispert S (2010) Alpha-synuclein deficiency leads to increased glyoxalase I expression and glycation stress. Cell Mol Life Sci (in press)Google Scholar
  47. Langer T, Levy RI, Strober W (1972) Metabolism of low-density lipoprotein in familial type-H hyperlipoproteinemia. J Clin Invest 51:1528–1536PubMedCrossRefGoogle Scholar
  48. Lyles GA, Chalmers J (1992) The metabolism of aminoacetone to methylglyoxal by semicarbazide-sensitive amino oxidase in human umbilical artery. Biochem Pharmacol 43:1409–1414PubMedCrossRefGoogle Scholar
  49. Maillard LC (1912) Action des acides amines sur les sucres: formation des melanoidines par voie methodique. Compt Rend Acad Sci 154:66–68Google Scholar
  50. Miyazawa N, Abe M, Souma T, Tanemoto M, Abe T, Nakayama M, Ito S (2010) Methylglyoxal augments intracellular oxidative stress in human aortic endothelial cells. Free Radic Res 44:101–107PubMedCrossRefGoogle Scholar
  51. Morcos M, Du X, Pfisterer F, Hutter H, Sayed AAR, Thornalley P, Ahmed N, Baynes J, Thorpe S, Kukudov G, Schlotterer A, Bozorgmehr F, El Baki RA, Stern D, Moehrlen F, Ibrahim Y, Oikonomou D, Hamann A, Becker C, Zeier M, Schwenger V, Miftari N, Humpert P, Hammes HP, Buechler M, Bierhaus A, Brownlee M, Nawroth PP (2008) Glyoxalase-1 prevents mitochondrial protein modification and enhances lifespan in Caenorhabditis elegans. Aging Cell 7:260–269PubMedCrossRefGoogle Scholar
  52. Myint T, Hoshi S, Ookawara T, Miyazawa N, Keiichiro M, Suzuki K, Taniguchi N (1995) Immunological detection of glycated proteins in normal and streptozotocin-induced diabetic rats using anti hexitol-lysine IgG. Biochim Biophys Acta 1272:73–79PubMedGoogle Scholar
  53. Nicolay JP, Schneider J, Niemoeller OM, Artunc F, Portero-Otin M, Haik G, Thornalley PJ, Schleicher E, Wieder T, Lang F (2006) Stimulation of suicidal erythrocyte death by methylglyoxal. Cell Physiol Biochem 18:223–232PubMedCrossRefGoogle Scholar
  54. Pedchenko VK, Chetyrkin SV, Chuang P, Ham AJ, Saleem MA, Mathieson PW, Hudson BG, Voziyan PA (2005) Mechanism of perturbation of integrin-mediated cell-matrix interactions by reactive carbonyl compounds and its implication for pathogenesis of diabetic nephropathy. Diabetes 54:2952–2960PubMedCrossRefGoogle Scholar
  55. Peters T (1996) All about albumin. Academic Press, New YorkGoogle Scholar
  56. Phillips SA, Thornalley PJ (1993) The formation of methylglyoxal from triose phosphates. Investigation using a specific assay for methylglyoxal. Eur J Biochem 212:101–105PubMedCrossRefGoogle Scholar
  57. Phillips SA, Mirrlees D, Thornalley PJ (1993) Modification of the glyoxalase system in streptozotocin-induced diabetic rats: effect of the aldose reductase inhibitor Statil. Biochem Pharmacol 46:805–811PubMedCrossRefGoogle Scholar
  58. Pratt JM, Petty J, Riba-Garcia I, Robertson DHL, Gaskell SJ, Oliver SG, Beynon RJ (2002) Dynamics of protein turnover, a missing dimension in proteomics. Mol Cell Proteom 1:579–591CrossRefGoogle Scholar
  59. Queisser MA, Yao D, Geisler S, Hammes HP, Lochnit G, Schleicher ED, Brownlee M, Preissner KT (2010a) Hyperglycemia impairs proteasome function by methylglyoxal. Diabetes 59:670–678PubMedCrossRefGoogle Scholar
  60. Queisser MA, Yao DC, Geisler S, Hammes HP, Lochnit G, Schleicher ED, Brownlee M, Preissner KT (2010b) Hyperglycemia impairs proteasome function by methylglyoxal. Diabetes 59:670–678PubMedCrossRefGoogle Scholar
  61. Rabbani N, Thornalley PJ (2008a) Dicarbonyls linked to damage in the powerhouse: glycation of mitochondrial proteins and oxidative stress. Biochem Soc Trans 036:1045–1050CrossRefGoogle Scholar
  62. Rabbani N, Thornalley PJ (2008b) The dicarbonyl proteome: proteins susceptible to dicarbonyl glycation at functional sites in health, aging, and disease. Ann N Y Acad Sci 1126:124–127PubMedCrossRefGoogle Scholar
  63. Rabbani N, Sebekova K, Sebekova K Jr, Heidland A, Thornalley PJ (2007) Protein glycation, oxidation and nitration free adduct accumulation after bilateral nephrectomy and ureteral ligation. Kidney Int 72:1113–1121PubMedCrossRefGoogle Scholar
  64. Rabbani N, Chittari MV, Zehnder D, Ceriello A, Thornalley PJ (2009) High dose metformin therapy reduces glycation and oxidative damage to apolipoprotein B100 and may decelerate atherosclerosis in patients with type 2 diabetes. Diabetologia 52:1293Google Scholar
  65. Rabbani N, Varma Chittari M, Bodmer CW, Zehnder D, Ceriello A, Thornalley PJ (2010) Increased glycation and oxidative damage to apolipoprotein B100 of LDL in patients with type 2 diabetes and effect of metformin. Diabetes 59:1038–1045PubMedCrossRefGoogle Scholar
  66. Reichard GA, Skutches CL, Hoeldtke RD, Owen OE (1986) Acetone metabolism in humans during diabetic ketoacidosis. Diabetes 35:668–674PubMedCrossRefGoogle Scholar
  67. Rosca MG, Mustata TG, Kinter MT, Ozdemir AM, Kern TS, Szweda LI, Brownlee M, Monnier VM, Weiss MF (2005) Glycation of mitochondrial proteins from diabetic rat kidney is associated with excess superoxide formation. Am J Physiol Renal Physiol 289:F420–F430PubMedCrossRefGoogle Scholar
  68. Ruoslahti E (1996) RGD and other recognition sequences for integrins. Annu Rev Cell Dev Biol 12:697–715PubMedCrossRefGoogle Scholar
  69. Santarius T, Bignell GR, Greenan CD, Widaa S, Chen L, Mahoney CL, Butler A, Edkins S, Waris S, Thornalley PJ, Futreal PA, Stratton MR (2010) GLO1—a novel amplified gene in human cancer. Genes Chromosom Cancer 49:711–725PubMedCrossRefGoogle Scholar
  70. Shinohara M, Thornalley PJ, Giardino I, Beisswenger PJ, Thorpe SR, Onorato J, Brownlee M (1998) Overexpression of glyoxalase I in bovine endothelial cells inhibits intracellular advanced glycation endproduct formation and prevents hyperglycaemia-induced increases in macromolecular endocytosis. J Clin Invest 101:1142–1147PubMedCrossRefGoogle Scholar
  71. Stevens VJ, Monnier VM, Cerami A (1980) Hemoglobin glycosylation as a model for modification of other proteins. Texas Rep Biol Med 40:387–396Google Scholar
  72. Stupack DG, Cheresh DA (2002) Get a ligand, get a life: integrins, signaling and cell survival. J Cell Sci 115:3729–3738PubMedCrossRefGoogle Scholar
  73. Tajika T, Bando I, Furuta T, Moriya N, Koshino H, Uramoto M (1997) Novel amino acid metabolite produced by Streptomyces sp.: taxonomy, isolation and structural elucidation. Biosci Biotechnol Biochem 61:1007–1010PubMedCrossRefGoogle Scholar
  74. Thangarajah H, Yao DC, Chang EI, Shi YB, Jazayeri L, Vial IN, Galiano RD, Du XL, Grogan R, Galvez MG, Januszyk M, Brownlee M, Gurtner GC (2009) The molecular basis for impaired hypoxia-induced VEGF expression in diabetic tissues. Proc Natl Acad Sci USA 106:13505–13510PubMedCrossRefGoogle Scholar
  75. Thornalley PJ (1988) Modification of the glyoxalase system in human red blood cells by glucose in vitro. Biochem J 254:751–755PubMedGoogle Scholar
  76. Thornalley PJ (1993) The glyoxalase system in health and disease. Mol Aspects Med 14:287–371PubMedCrossRefGoogle Scholar
  77. Thornalley PJ (1998) Glutathione-dependent detoxification of α-oxoaldehydes by the glyoxalase system: involvement in disease mechanisms and antiproliferative activity of glyoxalase I inhibitors. Chem Biol Interact 111–112:137–151PubMedCrossRefGoogle Scholar
  78. Thornalley PJ (2003a) Glyoxalase I—structure, function and a critical role in the enzymatic defence against glycation. Biochem Soc Trans 31:1343–1348PubMedCrossRefGoogle Scholar
  79. Thornalley PJ (2003b) The enzymatic defence against glycation in health, disease and therapeutics: a symposium to examine the concept. Biochem Soc Trans 31:1343–1348PubMedCrossRefGoogle Scholar
  80. Thornalley PJ (2005) Dicarbonyl intermediates in the Maillard reaction. Ann N Y Acad Sci 1043:111–117PubMedCrossRefGoogle Scholar
  81. Thornalley PJ (2008) Protein and nucleotide damage by methylglyoxal in physiological systems—role in ageing and disease. Drug Metab Drug Interact 23:125–150CrossRefGoogle Scholar
  82. Thornalley PJ, Strath M, Wilson RJM (1994) Anti-malarial activity in vitro of the glyoxalase I inhibitor diester, S-p-bromobenzylglutathione diethyl ester. Biochem Pharmacol 268:14189–14825Google Scholar
  83. Thornalley PJ, Edwards LG, Kang Y, Wyatt C, Davies N, Ladan MJ, Double J (1996) Antitumour activity of S-p-bromobenzylglutathione cyclopentyl diester in vitro and in vivo. Inhibition of glyoxalase I and induction of apoptosis. Biochem Pharmacol 51:1365–1372PubMedCrossRefGoogle Scholar
  84. Thornalley PJ, Langborg A, Minhas HS (1999) Formation of glyoxal, methylglyoxal and 3-deoxyglucosone in the glycation of proteins by glucose. Biochem J 344:109–116PubMedCrossRefGoogle Scholar
  85. Thornalley PJ, Battah S, Ahmed N, Karachalias N, Agalou S, Babaei-Jadidi R, Dawnay A (2003) Quantitative screening of advanced glycation endproducts in cellular and extracellular proteins by tandem mass spectrometry. Biochem J 375:581–592PubMedCrossRefGoogle Scholar
  86. Tsikas D, Mitschke A, Suchy MT, Gutzki FM, Stichtenoth DO (2005) Determination of 3-nitrotyrosine in human urine at the basal state by gas chromatography-tandem mass spectrometry and evaluation of the excretion after oral intake. J Chromatogr B 827:146–156CrossRefGoogle Scholar
  87. Vander Jagt DL, Robinson B, Taylor KK, Hunsaker LA (1992) Reduction of trioses by NADPH-dependent aldo–keto reductases (aldose reductase, methylglyoxal, and diabetic complications). J Biol Chem 267:4364–4369PubMedGoogle Scholar
  88. Venkatraman J, Aggarwal K, Balaram P (2001) Helical peptide models for protein glycation: proximity effects in catalysis of the Amadori rearrangement. Chem Biol 8:611–625PubMedCrossRefGoogle Scholar
  89. Wendler A, Irsch T, Rabbani N, Thornalley PJ, Krauth-Siegel RL (2009) Glyoxalase II does not support methylglyoxal detoxification but serves as a general trypanothione thioesterase in African trypanosomes. Mol Biochem Parasitol 163:19–27PubMedCrossRefGoogle Scholar
  90. Xiong JP, Stehle T, Zhang RG, Joachimiak A, Frech M, Goodman SL, Aranout MA (2002) Crystal structure of the extracellular segment of integrin alpha V beta 3 in complex with an Arg-Gly-Asp ligand. Science 296:151–155PubMedCrossRefGoogle Scholar
  91. Yao D, Brownlee M (2009) Hyperglycemia-induced reactive oxygen species increase expression of RAGE and RAGE ligands. Diabetes 59:249–255PubMedCrossRefGoogle Scholar
  92. Yao DC, Brownlee M (2010) Hyperglycemia-induced reactive oxygen species increase expression of the receptor for advanced glycation end products (RAGE) and RAGE ligands. Diabetes 59:249–255PubMedCrossRefGoogle Scholar
  93. Yao D, Taguchi T, Matsumura T, Pestell R, Edelstein D, Giardino I, Suske G, Rabbani N, Thornalley PJ, Sarthy VP, Hammes HP, Brownlee M (2007) High glucose increases angiopoietin-2 transcription in microvascular endothelial cells through methylglyoxal modification of mSin3A. J Biol Chem 282:31038–31045PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  1. 1.Clinical Sciences Research Institute, Warwick Medical SchoolUniversity of Warwick, University HospitalCoventryUK

Personalised recommendations